AOD-9604 for Body Recomposition

Candidate profile

Adults with stubborn visceral or abdominal adiposity that has resisted diet and exercise optimization — particularly those in a caloric deficit losing scale weight but not midsection fat. Also relevant for individuals who want GH's lipolytic benefit without diabetogenic, fluid-retention, and joint-related side effects.

AOD-9604 is not for individuals without a nutritional foundation. A caloric deficit or caloric maintenance is prerequisite — the peptide enhances lipolytic signaling but does not override energy balance.

Approach

Subcutaneous injection of AOD-9604 (modified GH fragment, amino acids 177–191) in the abdominal region. AOD-9604 retains the lipolytic activity of GH's fat-metabolizing domain without activating the IGF-1 axis — fat mobilization without the hyperglycemia, water retention, or acromegalic risks of full-length GH.

Protocol design

Primary peptide: AOD-9604, 250–300 mcg daily

Route: Subcutaneous injection, abdominal region (rotating injection sites within the periumbilical area)

Timing: Morning on an empty stomach, or before fasted cardio. AOD-9604's lipolytic effect is potentiated in a low-insulin environment — eating within 30 minutes before or after administration blunts the response.

Duration: 12 weeks minimum. Fat mobilization from visceral depots is a slow process; expecting visible results before 8 weeks is unrealistic.

Frequency: Daily, 7 days per week. No cycling is necessary during the 12-week window.

Optional addition: MOTS-c, 5 mg subcutaneous 2–3x per week — targets mitochondrial fatty acid oxidation, complementing AOD-9604's lipolytic signaling with improved substrate utilization.

Timeline & milestones

Weeks 1–3: No visible changes. AOD-9604 upregulates beta-3 adrenergic lipolysis, but mobilized fat must still be oxidized through activity. Compliance with exercise and nutrition determines downstream results.

Weeks 4–6: Early composition shifts. Scale weight may remain stable. Waist circumference and skinfold measurements are more reliable indicators. Some users report reduced abdominal bloating.

Weeks 8–12: Measurable recomposition in responders. DEXA or calipers should show reduced trunk fat percentage — most pronounced in those who maintained consistent deficit and exercise.

Monitoring

• Waist circumference: Measure weekly at the navel, same time of day (morning, post-void, pre-meal), same tension on the tape
• Body composition: DEXA scan or bioimpedance at baseline and week 12 — do not rely on scale weight alone
• Fasting glucose and insulin: AOD-9604 should not impair glucose metabolism (unlike full-length GH), but baseline and mid-cycle metabolic panels confirm this
• Injection site reactions: Mild redness or itching is common and transient; persistent nodules suggest technique adjustment is needed

When to adjust

• No measurable change in waist circumference by week 6: Audit nutrition and training compliance first. If confirmed, increase dose to 300 mcg. If still no response, AOD-9604 may not be the rate-limiting factor.
• Fasting glucose elevation: Discontinue and investigate — this is not expected with AOD-9604 and suggests a confounding variable or product quality issue.
• Appetite changes: AOD-9604 does not modulate appetite (unlike GLP-1 agonists). Significant changes suggest other variables have shifted.
• Post-12-week plateau: Take a 4-week break, then reassess whether a second cycle or a different approach is warranted.

Evidence reality check

AOD-9604 showed promise in early clinical trials, including a phase 2b trial demonstrating statistically significant fat loss versus placebo. However, it was not advanced through phase 3 and remains unapproved by major regulatory agencies. The lipolytic mechanism is biologically plausible, but clinical evidence is limited to early-phase trials. Treat AOD-9604 as an investigational adjunct, not a proven therapeutic.